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Abstract
Circulating tumor cells (CTCs) are cells shed from solid tumors into circulation and have been shown to be prognostic in the
setting of metastatic disease. These cells are obtained through a routine blood draw and may serve as an easily accessible
marker for monitoring treatment effectiveness. Because of the rapid progression of pancreatic ductal adenocarcinoma
(PDAC), early insight into treatment effectiveness may allow for necessary and timely changes in treatment regimens. The
objective of this study was to evaluate CTC burden as a biomarker of response to treatment with a oral
phosphatidylinositol-3-kinase inhibitor, BKM120, in patient-derived xenograft (PDX) mouse models of PDAC. PDX mice
were randomized to receive vehicle or BKM120 treatment for 28 days and CTCs were enumerated from whole blood before
and after treatment using a microfluidic chip that selected for EpCAM (epithelial cell adhesion molecule) positive cells. This
microfluidic device allowed for the release of captured CTCs and enumeration of these cells via their electrical impedance
signatures. Median CTC counts significantly decreased in the BKM120 group from pre- to post-treatment (26.61 to 2.21
CTCs/250 mL, p = 0.0207) while no significant change was observed in the vehicle group (23.26 to 11.89 CTCs/250 mL,
p = 0.8081). This reduction in CTC burden in the treatment group correlated with tumor growth inhibition indicating CTC
burden is a promising biomarker of response to treatment in preclinical models. Mutant enriched sequencing of isolated
CTCs confirmed that they harbored KRAS G12V mutations, identical to the matched tumors. In the long-term, PDX mice are
a useful preclinical model for furthering our understanding of CTCs. Clinically, mutational analysis of CTCs and serial
monitoring of CTC burden may be used as a minimally invasive approach to predict and monitor treatment response to
guide therapeutic regimens.
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Introduction
Tumor cells that are present in peripheral circulation, or
circulating tumor cells (CTCs), have been isolated from blood
samples of patient’s with many solid cancers. These cells are an
attractive target for staging and monitoring treatment effectiveness
because they are obtained noninvasively through a routine blood
draw and therefore can be measured serially throughout the
course of treatment. CTC burden has been shown to be predictive
of survival in metastatic breast, colorectal, prostate and lung
cancers [1–5]. CTCs have been isolated from patients with
pancreatic ductal adenocarcinoma (PDAC) but investigation of
their clinical utility has proven less successful than in other
epithelial cancers [6].
PDAC is a devastating disease characterised by early and
aggressive metastasis with a five year survival rate of ,5% [7].
Depending upon the extent of disease at diagnosis, the current
standard of care includes surgical resection, radiation therapy, and
chemotherapy with gemcitabine. Unfortunately .85% of patients
with PDAC present with disseminated or inoperable disease and
are not candidates for curative surgery [8]. New chemotherapeu-
tics and clinical approaches for treating PDAC are needed. The
Ras pathway is a highly sought after therapeutic target due to the
high frequency of KRAS mutations found in up to 95% of PDAC
[9]. Despite much effort, no anti-Ras therapies have been
successful. Currently, promising therapies focus on targeting
downstream effectors of Ras such as the Raf-MEK-ERK
mitogen-activated protein kinase (MAPK) and phosphatidylinosi-
tol-3-kinase (PI3K)-AKT signaling pathways [10]. PI3K is an
attractive therapuetic target as it is one of the main Ras effector
signaling pathways, is involved in tumor growth and maintenance,
and has also been reported to be mutated in pancreatic cancers
[11], [12], [13]. Ras is known to directly interact with the p110a
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catalytic subunit of PI3K and this interaction is imporant for Ras-
driven tumor formation [14], [15]. Given this, therapeutically
targeting the p110a catalytic subunit may be effective in tumors
harboring either KRAS or PI3KCA mutations. BKM120 is an oral
pan-class 1 PI3K inhibitor that inactivates the p110a subunit and
is currently in Phase I–III clinical trials [16]. To date, the
effectiveness of BKM120 in PDAC is unknown. However, in vitro
studies of various cancer cell lines have shown that BKM120
decreases phosporylated-Akt (p-Akt) levels, inhibits signaling
pathways downstream of PI3K and p-Akt, and induces apoptosis
[17].
Patient-derived xenografts (PDX) are known to be an excellent
preclinical model for oncology drug development and biomarker
discovery. PDX mouse models are created by engrafting surgically
resected patient tumor samples subcutaneously in immunocom-
promised mice. PDX tumors can be passaged over time and
expanded into subseqent generations of mice while still maintain-
ing the tumor architecture, genetic heterogeneity, and mutational
profile as the primary tumor [18], [19]. PDX more accurately
model the primary tumor than traditional cell-line derived
xenografts that are more genetically homogenous and have
adapted to growth ex-vivo. However, studies of CTCs in preclinical
models has been limited to cell–line derived xenografts or
genetically engineered mice to date [20], [21].
To assess CTC burden in our preclinical model, a novel
microfluidic chip that selects for EpCAM positive cells from as
little as 250 mL of whole blood was used. This microfluidic chip
allows for captured CTCs to be released from the capture surface
for enumeration using unique electrical impedance signatures of
CTCs as they pass through two platinum (Pt) electrodes. The
electrical impedence enumeration has high sensitivity and
specificity for CTCs based on their size and electrical properties
compared to any contaminating leukocytes or red blood cells [22],
[23]. In addition, the microfluidic chip has been shown to
demonstrate high clinical sensitivity, even for PDAC CTCs when
using EpCAM positive selection, providing the ability to collect
sufficient numbers of CTCs to monitor drug response in PDX
models using non-terminal bleeds [24].
As more personalized therapies like BKM120 become available
to treat PDAC, clinicians will have the flexibility to personalize
therapies to achieve optimal response. Biomarkers such as CTCs
may guide therapy in several ways. First, early insight into
treatment effectiveness by monitoring CTC burden may help
guide changes in therapy. Second, CTC mutational status, which
may or may not be entirely the same as the primary tumor, may
guide therapy selection. Third, profiling changes in CTC gene
expression may predict treatment resistance [20]. Because PDAC
has such a rapid progression and poor prognosis, early evaluation
of treatment effectiveness and early intervention in these patients is
of great importance for prolonging survival and improving quality
of life. Therefore the objective of this study was to first evaluate
CTCs in patient derived xenograft (PDX) mouse models of PDAC
and secondly to evaluate CTC burden as a biomarker for response
to targeted treatment with BKM20.
Materials and Methods
PDX Cohort Expansion
PDAC tumor tissue from a de-identified patient was obtained
from the University of North Carolina Institutional Review Board
(IRB) approved tissue procurement facility after IRB approval.
Tumor tissue was engrafted subcutaneously into the flanks of
NSG/NOD mice, expanded, and passed over time. All animal
experiments were carried out ethically under protocols approved
by the University of North Carolina Institutional Animal Care and
Use Committee (protocol # 12–314).
Treatment
Treatment was begun when tumors reached a median size of
240 mm3 (range = 121–487 mm3) in the expansion cohort. Mice
were randomized and dosed with either vehicle or BKM120
(40 mg/kg) by oral gavage (o.g.) once daily for 28 days. BKM120
was suspended in 1 volume NMP (1-methyl-2-pyrrolidone): 9
volumes PEG300 with a total application volume of 10 mL/kg
[25]. Mice in the vehicle group were treated with NMP/PEG300
vehicle with a total application volume of 10 mL/kg. Caliper
measurements were performed twice weekly and tumor volume
was calculated using the formula [K (width 6 length2)]. On
treatment day 28, the mice were euthanized and the tumors
harvested and flash frozen for subsequent analysis.
Microfluidic Chip Fabrication
The microfluidic chip that was used to capture CTCs in this
study consists of 51 sinusoidally shaped channels, 30 mm wide and
150 mm deep, that has been optimized to isolate CTCs from small
volumes of whole blood (Figure 1, A–E) [22]. Microfluidic chips
were hot-embossed into PMMA as previously described [23].
Following ultraviolet modification of the microfluidic channels,
cover slips were annealed to the chips at 98uC for 25 min.
Monoclonal anti-human EpCAM antibodies (R&D Systems) were
immobilized to the microfluidic channels in a two step process.
First, a solution of 200 mg/mL of EDC (1-ethyl-3-[3-dimethyla-
minopropyl] carbodiimide hydrochloride) (ThermoScientific) and
50 mg/mL of NHS (N-hydroxysuccinimide) (ThermoScientific) in
100 mM MES (2-[4-morpholino]-ethane sulfonic acid) (pH = 4.83)
was infused into the microfluidic chip and incubated at room
temperature for 10 min. Following incubation, the EDC/NHS
solution was replaced with 0.5 mg/mL monoclonal anti-human
EpCAM antibodies in PBS (pH = 7.4) and allowed to react
overnight at 4uC. Prior to CTC capture, each microfluidic chip
was rinsed with a solution of phosphate-buffered saline (PBS) to
remove any nonspecifically bound antibody at a flow rate of
55 mL/min.
CTC Isolation and Enumeration
On day 0 prior to treatment with BKM120 or vehicle, blood
was collected from each mouse via a submandibular bleed.
Terminal bleeds were performed via cardiac puncture on
treatment day 28. Blood was collected in ethylenediaminetetra-
acetic acid (EDTA) tubes and processed within five hours of
collection. To isolate CTCs from whole blood, blood was
introduced into the microfluidic chips at a flow rate of 27.5 mL/
min. Processed blood volumes for the day 0 samples ranged from
180–380 mL (mean = 255 mL); volumes of the day 28 samples
ranged from 650–1000 mL (mean = 929 mL) The chips were then
washed with 0.2 mL of PBS at a flow rate of 55 mL/min.
Captured cells were released from the microfluidic chip with
0.25% trypsin for enumeration using electrical impedance
signatures of CTCs. Impedance measurements were obtained
using previously described, home-built circuitry, capable of
detecting single tumor cells as they travel through the detection
electrodes with high sensitivity and specificity [22]. Data were
collected using NI-USB-6009 (National Instruments) data acqui-
sition board and software written in LabView (National Instru-
ments). After Gaussian filtering, peaks in the data trace that were
greater than 10 times the standard deviation of the background
noise were considered significant and counted as CTCs using a
custom user interface in MATLAB.
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Immunofluorescence
Staining was performed directly on the microfluidic chip
following CTC isolation from whole blood. 0.25% Bovine Serum
Albumin (BSA) in PBS buffer (pH 7.4) was infused through the
microfluidic chip for 10 min at a flow rate of 20 mL/min. Next,
100 mL of 0.0025 mg/mL of anti-mouse CD45-FITC (HI30
clone; eBiosciences) was infused at a flow rate of 10 mL/min and
incubated at 4uC for 1 hour followed by a 5 min wash of 0.02%
TX-100/PBS at 20 mL/min. For fixation and permeabilization,
2–4% paraformaldehyde in PBS buffer was infused at a flow rate
of 15 mL/min for 10 min followed by 0.1% TX-100 in PBS buffer
at a flow rate of 15 mL/min for 10 min. Next, 100 ml of a panel of
0.01 mg/mL anti-Cytokeratins 8, 19 labeled with Texas Red
(eBiosciences) was infused through the device at 10 mL/min and
incubated at 4uC for ,1 hour, followed with a 10 min wash of
0.25% BSA in PBS at 20 mL/min. For nuclear staining,
0.001 mg/mL DAPI (Thermo Pierce Technologies) in PBS was
infused at a flow rate of 15 mL/min for 7 min followed by a final
15 min wash with 0.25% BSA in PBS.
The CTC microfluidic chip was manually scanned on an
inverted Olympus 1671 microscope (Center Valley, PA) using
10x, 20x, 40x, and 60x dry objectives equipped with a high
resolution (134461024) CCD camera (Hamamatsu ORCA-03G)
and a mercury arc lamp as an illumination source. Images were
collected and analyzed using Metamorph imaging software
(Olympus).
DNA Isolation
After CTCs were enumerated via electric impedance measure-
ments, they were collected in 100 uL Fetal Bovine Serum (FBS)
and stored at 280uC. At the time of DNA isolation, samples were
thawed and centrifuged at 10,000 RPM for 2 min to sequester
cells at the bottom of the collecting tube. All but 100 mL of
supernatant was removed and cells were resuspended in 350 mL of
Buffer RLT Plus (Qiagen). The sample was then vortexed for 30
seconds and CTC DNA was isolated using the AllPrep DNA Kit
(Qiagen) or the QIAamp DNA Micro Kit (Qiagen). Tumor DNA
was isolated using the AllPrep DNA Kit.
Mutational Analysis of Tumor DNA
Direct sequencing mutational analysis was performed for PI3K
codons 542, 545, and 1047, and KRAS codons 12 and 13 using
polymerase chain reaction (PCR) amplification followed by
pyrosequencing (Pyromark MD, Qiagen). For sequencing of
Figure 1. CTC isolation using a microfluidic chip. (A) Design of the CTC microfluidic chip with sinusoidally shaped capture channels and
brightfield images of (B) the capillary tube inserted into the on-chip entry channel where whole blood enters the microfluidic chip, (C) sinusoidally
shaped capture channels where anti-human EpCAM antibodies are immobilized for CTC capture, (D) exit channel, and (E) impedance sensor with two
Pt electrodes located adjacent to the exit channel to detect released CTCs. (F) Cells captured from whole blood of PDX-tumor bearing mice visualized
directly on the microfluidic chip following immunostaining with DAPI (blue), human cytokeratin 8/19 (CK, red), and mouse CD45 (green). The staining
pattern of DAPI-positive, human CK-positive, and mouse CD45-negative is characteristic of human CTCs. (G) A rare contaminating mouse leukocyte
bound non-specifically to the microfluidic chip stained DAPI-positive, human CK-negative, and mouse CD45-positive. Contaminating leukocytes were
excluded from enumeration due to the high specificity of the electrical impedance detector for cancer cells.
doi:10.1371/journal.pone.0089474.g001
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PI3K codons 542, 545, and 1047, PCR of exons 9 and 20 was
performed using the following primers: exon 9, 59–/BioTEG/
ATTTCTACACGAGATCCTCTCTCT39 and 59–CCATTT-
TAGCACTTACCTGTGAC–39; exon 20, 59– TGAGCAA-
GAGGCTTTGGAGTAT–39 and 59–/BioTEG/TGCTGT-
TTAATTGTGTGGAAGATC–39. PCR amplification was done
for 45 cycles with an annealing temperature of 62uC. PCR
products were analyzed by pyrosequencing using the internal
primers: codon 542, 59–TTCTCCTGCTCAGTGAT– 39; codon
545, 59– TAGAAAATCTTTCTCCTG–39; codon 1047, 59–
GAAACAAATGAATGATGC–39.
For sequencing of KRAS codons 12 and 13, PCR of exon 2 was
performed using the primers: 59–CGATGGAGGAGTTTG-
TAAATGAA–39and 59–/BioTEG/TTCGTCC ACAAAAT-
GATTCTGA–39. PCR amplification was done for 55 cycles with
an annealing temperature of 68uC. PCR products were analyzed
by pyrosequencing using the internal primer 59–
AAACTTGTGGTAGTTGGA–39.
KRAS Mutational Analysis of CTCs
MES protocols for KRAS codon 12 have previously been defined
[26], [27]. In brief, the first PCR was performed using 16
Immomix buffer with 4 mL of CTC DNA sample, and 10 mM of
each primer. The primers used were: 59– ACTGAATA-
TAAACTTGTGGTAGTTGGACCT–39 and 59– TCAAA-
GAATGGTCCTGGACC– 39. Touchdown PCR was used for
the first round of amplification to selectively amplify the human
KRAS gene. After an initial 15 min at 94uC, cycling conditions
were 60 s at 94uC, 40 s at 62uC, 40 s at 72uC. For the next 10
cycles the annealing temperature was decreased by 0.5uC for each
cycle until a final annealing temperature of 57.5uC was reached.
Products were subjected to an additional 30 cycles (60 s at 94uC,
40 s at 57.5uC, 40 s at 72uC) of PCR. PCR products were then
purified, quantified, and subjected to restriction digest by the
addition of BstNI and NEBuffer 3.1(New England Biolabs) for
16 hours at 60uC. Restriction digested products were then diluted
to a final concentration of 1–2 ng of DNA/mL.
The second round of PCR was done using the primers 59–/
BIOTEG/ACTGAATATAAACTTGTGGTAGTTGGACCT– 39
and 59– TAATATGCATATTAAAACAAGATTTACCTC– 39,
for 40 cycles (60 s at 94uC, 40 s at 54uC, 40 s at 72uC). PCR
products were analyzed using pyrosequencing (Pyromark MD,
Qiagen) using the internal primer 59– CGTCAAGG-
CACTCTTGCC–39.
Statistical Analysis
Statistical analysis was performed to compare CTCs enumer-
ated from non-tumor bearing mice to PDX-tumor bearing mice,
change in CTC burden with treatment, and change in tumor
volume with treatment. CTC data was analyzed using a non-
parametric test (Wilcoxon-Mann-Whitney test) because the data
had a non-Gaussian distribution. Tumor volume data had a
Gaussian distribution and was analyzed using a parametric test
(unpaired t-test). Statistical analysis of absolute CTC burden vs.
absolute tumor volume and change in CTC burden vs. change in
tumor volume was performed using Pearson correlation.
Results and Discussion
Isolation and Enumeration of CTCs from PDAC PDX Mice
Whole blood was introduced directly into the microfluidic chip
without pre-processing and EpCAM positive cells were selected for
by interaction with anti-human EpCAM immobilized to the walls
of the microfluidic channels. To verify that CTCs were captured
on the microfluidic chip, immunofluorescence staining was
performed directly within the microfluidic chip. One accepted
method for identification of CTCs via immunofluorescence is
nuclear staining (DAPI) positive, epithelial cytokeratin (CK)
positive, and leukocyte CD45 negative [28]. Captured cells stained
DAPI-positive, human CK 8/19-positive, and mouse CD45-
negative, confirming their identity as CTCs (Figure 1, F). Non-
specifically bound leukocytes were also found within the micro-
fluidic chip, staining DAPI-positive, human CK 8/19-negative,
and mouse CD45-positive (Figure 1, G). From seven samples
analyzed by immunofluorescence staining, the purity of captured
CTCs to contaminating leukocytes was 89% (range 62–100%),
with an average count of 1.5 leukocytes per 250 mL of processed
blood (range 0–5 leukocytes/250 mL).
Unfortunately, immunofluorescence staining within the micro-
fluidic chip and manually locating and identifying CTCs is time
intensive. To automate the enumeration process, captured cells
were released from the capture surface and enumerated based on
impedance measurement which is capable of discriminating
cancer cells from contaminating leukocytes based on cell size as
the cells passed between two Pt electrodes. Previous investigation
into the specificity of using impedance for enumerating cancer
cells showed that there is only minimal misclassification (,15%)
when this method is used to identify cancer cells vs. leukocytes.
This misclassification rate correlated with the overlap in the size
distribution of these two cell populations [24]. Enumeration of
CTCs by impedance measurements allowed for a fully automated
enumeration process.
Previous work from the Haber laboratory using a similar CTC
microfluidic chip showed that CTCs, defined by a staining pattern
of CK-positive, EpCAM-positive, and CD45-negative, were found
at a very low level in blood from healthy subjects (median = 1.2
CTCs/100 mL, range = 0–2.2 CTCs/100 mL) [20]. The capabil-
ity our microfluidic chip to accurately detect and enumerate CTCs
by impedance as well as the absence of CTC burden in healthy
controls was confirmed in this study through the processing and
enumeration of CTCs from whole blood from non-tumor bearing
PDX mice and PDAC PDX mice. Zero CTCs were enumerated
from four out of five non-tumor bearing PDX mice (median = 0
CTCs/250 mL, range = 0–1 CTCs/250 mL), while CTCs were
enumerated from 31 of 31 PDAC PDX mice (median = 11
CTCs/250 mL, range = 1–83 CTCs/250 mL) (p = 0.0008, Wil-
coxon) (Figure 2). While 1 non-tumor bearing PDX sample had a
positive reading, only one cell was responsible for this false positive
reading. Our immunofluorescence staining results showing that
leukocyte contamination is found on the microfluidic chip with an
average count of 1.5 leukocytes per 250 mL of processed blood
(range 0–5 leukocytes/250 mL), coupled with the ,15% misclas-
sification rate between CTCs and leukocytes using impedance
enumeration, suggests that we expect an average false positive rate
of only 0.225 cells per 250 mL of processed blood (range 0–
0.75 cells/250 mL). The presence of only 1 out of 5 non-tumor
bearing mice with a false positive reading of one cell is in
concordance with these expectations. Therefore, impedance is an
accurate method for detection of CTCs given the high purity of
CTCs captured on the microfluidic chip (89%), the low
misclassification rate (,15%) between cancer cells and leukocytes,
and the significantly higher burden of CTCs enumerated from
tumor-bearing PDX mice.
CTC Response to BKM120 Treatment
A cohort of PDX mice was expanded from a de-identified
PDAC patient tumor. Hematoxylin and eosin staining showed that
the PDX tumor tissue maintained a similar histological architec-
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ture as the primary patient tumor with marked desmoplastic
stroma (Figure 3). Mice were randomized to receive vehicle or
BKM120 for 28 days. Blood was collected from PDX mice for
CTC enumeration on day 0 prior to the first treatment with
BKM120 or vehicle and again on day 28. On day 0, there was no
significant difference in baseline CTC counts between the
BKM120 group and vehicle group (p = 0.8081). Median CTC
burden significantly decreased in the BKM120 group from pre- to
post-treatment, with one mouse having no detectable CTCs at
post-treatment (pre-treatment, pre: median = 26.61 CTCs/
250 mL, range = 7–63 CTCs/250 mL, n = 8; post-treatment, post:
median = 2.21 CTCs/250 mL, range = 0–79 CTCs/250 mL,
n = 8; p = 0.0207, Wilcoxon) while no significant change was
observed in the vehicle group (pre: median = 23.26 CTCs/
250 mL, range = 4–43 CTCs/250 mL, n = 4; post: median
= 11.89 CTCs/250 mL, range = 6–146 CTCs/250 mL, n = 8;
p = 0.8081, Wilcoxon) (Figure 4). The reduction in CTC burden
that was observed in the BKM120 treatment group suggests that
changes in CTC burden may be used to non-invasively monitor
response to therapy in patients with pancreatic cancer.
Tumor Response to BKM120 Treatment
We then evaluated whether this decrease in CTC burden with
BKM120 treatment was associated with tumor response. Tumor
volumes in the BKM120 treatment group and vehicle group were
the same pre-treatment (BKM120 group: mean = 256 mm3,
standard deviation (SD) = 105 mm3, n = 9 vs. vehicle group:
mean = 255 mm3, SD = 133 mm3, n = 8). Mean tumor volume
after 28 days of treatment in the BKM120 group was 436 mm3
(SD = 270 mm3) compared to 540.49 mm3 (SD = 301 mm3) in
the vehicle group. BKM120 treatment inhibited tumor growth
(fold change, FC = 1.56, SEM = 0.148) compared to vehicle (FC
= 2.16, SEM = 0.221, p = 0.0185, t-test) over 28 days of treatment
(Figure 5).
Correlation between CTC Burden and Tumor Volume
To evaluate CTC burden as a biomarker for tumor volume,
correlation between absolute CTC burden and absolute tumor
volume from day 0 data was analyzed (Table 1). We found a
positive but not statistically significant correlation between CTC
burden and tumor volume (R = 0.558, p = 0.0547). To evaluate
the change in CTC burden as a biomarker for response to therapy,
we looked at the correlation between fold change in CTC burden
and fold change in tumor volume over 28 days (Table 1). We
found a significant correlation between the change in CTC counts
and the change in tumor burden (R = 0.744, p = 0.004). However,
the change in CTC count data appeared to be non-normal and
the occurrence of mice with zero detected CTCs limited log
Figure 2. CTC enumeration from PDX-tumor bearing mice. CTCs
captured and enumerated from whole blood of non-tumor and tumor
bearing PDX mice. Five non-tumor bearing mice were analyzed for their
CTC level (median = 0 CTCs/250 mL, range = 0–1 CTCs/250 mL),
while CTCs were enumerated from 31 of 31 PDAC PDX mice (median
= 11 CTCs/250 mL, range = 1–83 CTCs/250 mL) (p = 0.0008, Wilcoxon).
doi:10.1371/journal.pone.0089474.g002
Figure 3. Patient and PDX tumor. H&E staining of the de-identified
patient tumor (A, B) and corresponding PDX tumor (C, D). Both the
patient and PDX tumors are consistent with PDAC with desmoplastic
stroma (206magnification).
doi:10.1371/journal.pone.0089474.g003
Figure 4. Response of CTC burden to BKM120 treatment. PDAC
PDX mice were treated with vehicle or BKM120 for 28 days. CTCs were
enumerated from whole blood on day 0 prior to the first treatment and
on day 28 after the last treatment. CTC counts significantly decreased in
the BKM120 group from pre- to post-treatment (pre-treatment, pre:
median = 26.61 CTCs/250 mL, range = 7–63 CTCs/250 mL, n = 8; post-
treatment, post: median = 2.21 CTCs/250 mL, range = 0–79 CTCs/
250 mL, n = 8; p = 0.0207, Wilcoxon) while no significant change was
observed in the vehicle group (pre: median = 23.26 CTCs/250 mL, range
= 4–43 CTCs/250 mL, n = 4; post: median = 11.89 CTCs/250 mL, range
= 6–146 CTCs/250 mL, n = 8; p = 0.8081, Wilcoxon) One post BKM120
treatment sample had no detectable CTCs and is not plotted on scale.
doi:10.1371/journal.pone.0089474.g004
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transformation. These results show a stronger correlation between
the change in tumor volume and the change in CTC burden than
between the absolute number of CTCs and tumor size. This
suggests that serially monitoring CTC burden over time to
monitor response to therapy may be more clinically useful than
using CTCs as a biomarker of actual tumor burden.
Tumor and CTC DNA Mutation Analysis
Sequencing of DNA extracted from PDX tumor samples
showed that the primary tumor was PI3KCA wild type at codons
542, 545, 1047 and KRAS G12V mutant at codon 12. To
determine if CTCs were shed from the tumor MES of KRAS codon
12 was performed following CTC isolation. DNA was successfully
extracted from 16 of 34 CTC samples. 81% (13/16) of the
extracted DNA samples were of sufficient quality for mutational
analysis. 100% (13/13) of CTC samples analyzed with MES had
KRAS G12V mutations, which corresponded with the KRAS
mutational status of matched PDX tumors, confirming capture of
PDX associated CTCs.
Conclusion
While much work has been done to prove the prognostic value
of CTC levels in breast, colorectal, prostate and lung cancers, little
progress has been made in this area for pancreatic cancer due to
the poor sensitivity of many CTC assays for patients with PDAC
[1–5]. Given the high sensitivity of our CTC assay for PDAC
patients and the rapid deterioration of patients once they are
diagnosed, a preclinical model for studying CTCs in PDAC is
especially important [24]. The highly sensitive microfluidic chip
used in this study was capable of detecting and enumerating CTCs
from only 250 mL of PDAC PDX mouse blood. Downstream
MES of isolated CTCs also showed that they harbored G12V
KRAS mutations, as did the matched primary tumors, which is
significant as it confirmed our method successfully isolated PDX
derived CTCs. Cell line xenograft mice and genetically engineered
mice have been used as preclinical models to study CTCs
previously, but these model systems are limited by their inability to
replicate the very heterogeneous population of cells found in
human tumors [20], [21]. Our data suggests that PDX mice can
be a useful preclinical model for studying CTCs. PDX mice
harbor human tumor tissue and thus may prove to be a better
model system for studying the significance of CTC burden.
Tumor growth inhibition with BKM120 was modest in this
study and may be explained by the primary tumor being PI3KCA
wild type and KRAS mutant. It has been shown that KRAS
activating mutations are predictive of resistance to the PI3K
inhibitor, PX-866, while PI3KCA mutations are predictive of
sensitivity [29]. Therefore, future work with models that are KRAS
wild type and harbor PI3KCA activating mutations may show a
more robust response to BKM120.
Previous work in patients with epithelial based cancers showed
that the absolute number of CTCs found in circulation did not
correspond to tumor size. However, in a small cohort of these
patients, serial measurements of CTC burden and radiographic
tumor volume showed a correlation between response to treatment
and no-response to treatment [30]. Similarly, prior work with
breast cancer patients undergoing therapy did not find a
correlation between CTC burden and radiographic evidence of
tumor volume. However, the results did show that CTC burden at
first follow up was a better marker for predicting survival than
radiographic evidence of response [31]. In agreement with these
prior studies, our results show stronger evidence for a correlation
between change in tumor volume and change in CTC burden
than for absolute number of CTCs correlating to tumor volume.
This suggests that serially monitoring CTC burden over time to
monitor response to therapy may be more clinically useful than
using CTCs as a biomarker for tumor burden.
More studies will also be needed to determine whether CTCs
may be utilized as an early biomarker for response to treatment
before change in tumor volume is evident. To better assess this,
treatment could be continued for longer than 28 days allowing
time for a more pronounced response in tumor volume to be
observed. A longer course of treatment would also allow for serial
measurements of CTC burden over time.
Figure 5. Tumor growth inhibition with BKM120 treatment.
BKM120 treatment of PDAC PDX mice for 28 days inhibited tumor
growth (Mean fold change, FC = 1.56; SEM = 0.148; n = 9) compared to
vehicle (mean FC = 2.16; SEM = 0.221; n = 8, p = 0.0185, t-test).
doi:10.1371/journal.pone.0089474.g005













Vehicle 364 147.9 239.1 1.6 42.9 10.3 0.2
Vehicle 368 158.4 267.2 1.7 9.9 6.9 0.7
Vehicle 375 126.0 304.0 2.4 36.9 12.5 0.3
Vehicle 391 239.1 405.0 1. 79 - 145.6 -
Vehicle 735 379.8 668.3 1.8 - 67.1 -
Vehicle 739 487.7 1028.5 2.1 - 11.3 -
Vehicle 740 379.3 968.0 2. 65 - 5.6 -
Vehicle 743 121.0 416.0 3.4 4.2 21.4 5.1
BKM120 361 137.3 117.0 0.9 8.8 - -
BKM120 363 288.0 575.0 2.0 44.0 2.5 0.1
BKM120 365 147.9 208.3 1.4 20.8 3.0 0.1
BKM120 371 309.0 627.0 2.0 - 79.3 -
BKM120 387 272.0 384.8 1.4 27.5 0.2 0.0
BKM120 388 147.9 147.9 1.0 32.0 14.5 0.5
BKM120 736 210.9 343.2 1.6 25.7 1.9 0.1
BKM120 741 487.7 1028.0 2.1 63.5 0.2 0.0
BKM120 747 304.0 496.4 1.6 6.9 0 0
(-) No data due to microfluidic chip failure.
doi:10.1371/journal.pone.0089474.t001
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In the long-term, PDX mice may be a useful preclinical model
for further studying the prognostic significance of CTCs and their
role in metastasis. Our results demonstrate that CTC burden may
be a useful biomarker of response to targeted therapy in PDX
mouse models of pancreatic cancer. These results suggest that
monitoring of CTC burden in patients over the course of
treatment could provide early evidence of treatment response to
guide therapeutic changes and limit unnecessary prolonged
exposure to toxic treatments. Investigating the mutational status
of CTCs with MES could also help to identify patients that would
be most responsive to mutation targeted therapy, thus serving as a
minimally invasive ‘‘liquid biopsy.’’
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